Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab plus conventional treatment for severe or critical COVID-19
ChiCTR2000030089Phase 4Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Time to clinical improvement. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030089.